What's Hot

View all perspectives
      RT @ericdeinmd: #EULAR2022 LB0001
      Bimekizumab (IL-17F and IL-17A) in bionaive PsA
      BE OPTIMAL phase 3 trial, 24 weeks
      ⭐

      Eric Dein ericdeinmd

      2 years 5 months ago
      #EULAR2022 LB0001 Bimekizumab (IL-17F and IL-17A) in bionaive PsA BE OPTIMAL phase 3 trial, 24 weeks ⭐️Met Primary endpt - ACR50 ⭐️Met other ACR and PASI endpts ⭐️Safety: higher fungal infections @RheumNow https://t.co/x8u6B93FNl
      RT @synovialjoints: Who remotely enters PROs online? Glintborg et al from the Danbio Registry showed that patients who u

      Dr. Antoni Chan synovialjoints

      2 years 5 months ago
      Who remotely enters PROs online? Glintborg et al from the Danbio Registry showed that patients who used the system were mainly 40-80 years of age, on biologics and had lower HAQ score. Disease duration and diagnosis had no impact, reminders helped #EULAR2022 @RheumNow POS0373 https://t.co/voCfGiJgwm
      RT @RichardPAConway: Fascinating! Richette et al. Machine learning identifies 8 clusters of PsA phenotypes. Treatment re

      Richard Conway RichardPAConway

      2 years 5 months ago
      Fascinating! Richette et al. Machine learning identifies 8 clusters of PsA phenotypes. Treatment responses seem to differ, being better in cluster 2 and worse in cluster 5 and 6 (at least for IL23i guselkumab). @RheumNow #EULAR2022 POS1055 https://t.co/QIh2SbJKpa
      RT @RichardPAConway: Magrey et al. IL23i Risankizumab improves enthesitis in PsA @RheumNow #EULAR2022 POS1057 https://t.

      Richard Conway RichardPAConway

      2 years 5 months ago
      Magrey et al. IL23i Risankizumab improves enthesitis in PsA @RheumNow #EULAR2022 POS1057 https://t.co/BjuYj6xUdZ
      RT @KDAO2011: Wow! Phase 2 #deucravacitinib data for #SLE met primary & secondary endpoints: SRI(4) response, BICLA,

      TheDaoIndex KDAO2011

      2 years 5 months ago
      Wow! Phase 2 #deucravacitinib data for #SLE met primary & secondary endpoints: SRI(4) response, BICLA, LLDAS, CLASI-50. AEs include: skin related events and UTIs but no increase in SIE, HZ, MACE/VTE @bmsnews LB0004 #EULAR022 @rheumnow https://t.co/bsKI0mixVT
      RT @Yuz6Yusof: #POS1236 #EULAR2022 More data to justify safety of #COVID vaccination to our #lupus patients. A study in

      Md Yuzaiful Md Yusof Yuz6Yusof

      2 years 5 months ago
      #POS1236 #EULAR2022 More data to justify safety of #COVID vaccination to our #lupus patients. A study in Italy (>450 pts) found 1/4 had side effects (mostly mild) and 4% had a flare. These side effects were more common in those on >1 DMARDS and Belimumab @RheumNow https://t.co/mNS6rQfsSq
      RT @drdavidliew: BRIDGE-PMR (rituximab in PMR) routine care extension to 52w
      (in #PMRGCAJC one big qu asked was ?sustain

      David Liew drdavidliew

      2 years 5 months ago
      BRIDGE-PMR (rituximab in PMR) routine care extension to 52w (in #PMRGCAJC one big qu asked was ?sustained benefit) sustained benefit (RR 2.5 GC-free remission) steroid-sparing (PNL 1.6g v 2.3g) & ritux ?cheap enough now but COVID calculus difficult POS0269 #EULAR2022 @RheumNow https://t.co/Ln2ArclKO8 https://t.co/OtCwdjIPeL
      RT @synovialjoints: What guides treatment decisions in AxSpA? Bolt et al showed patients assessed in clinical remission,

      Dr. Antoni Chan synovialjoints

      2 years 5 months ago
      What guides treatment decisions in AxSpA? Bolt et al showed patients assessed in clinical remission, 1/3 had BASDAI >3.5. Treatment unchanged as low disease activity, awaiting effects of current Rx, complaints not related to axSpA, patient preference #EULAR2022 @RheumNow POS0303
      RT @synovialjoints: Treatment of active SpA improves depressive symptoms in SpA with HADS-D score reducing. This was gre

      Dr. Antoni Chan synovialjoints

      2 years 5 months ago
      Treatment of active SpA improves depressive symptoms in SpA with HADS-D score reducing. This was greatest for TNFi followed by NSAIDs and csDMARDs. TNFi reduced the proportion of patients (48% to 29%) with depressive symptoms at follow up Webers et al #EULAR2022 @RheumNow POS0304
      RT @RichardPAConway: Morand et al Tyk2i deucravacitinib in SLE. 48-week phase 2 RCT. SRI(4) PBO: 34.4%; DEUC 3 mg BID:

      Richard Conway RichardPAConway

      2 years 5 months ago
      Morand et al Tyk2i deucravacitinib in SLE. 48-week phase 2 RCT. SRI(4) PBO: 34.4%; DEUC 3 mg BID: 58.2%, P =0.0006; DEUC 6 mg BID: 49.5%, P =0.021; DEUC 12 mg QD: 44.9%, P =0.078. BICLA, LLDAS, CLASI-50, active joint count also+ @RheumNow #EULAR2022 LB0004 https://t.co/MBPc9xQFvG https://t.co/n3GUwl0RtD
      RT @AurelieRheumo: BE OPTIMAL Phase 3 RCT

      Bimekizumab dual IL17A & F inhibitor in bionaive PsA

      ⭐️ACR50 wk 16

      Aurelie Najm AurelieRheumo

      2 years 5 months ago
      BE OPTIMAL Phase 3 RCT Bimekizumab dual IL17A & F inhibitor in bionaive PsA ⭐️ACR50 wk 16 43.9% vs 10% PBO ⭐️PASI 90 wk 16 61% vs. 3% PBO ⭐️separation from wk 4 Safety: fungal injections BKZ > ADA @RheumNow LB0001 #EULAR2022 https://t.co/7ZwV1XDSNb
      RT @ericdeinmd: PAISLEY LB004
      @EricFMorand on deucravacitinib phase 2 for SLE
      ⭐️Meets primary endpt: SRI(4)
      ⭐️Se

      Eric Dein ericdeinmd

      2 years 5 months ago
      PAISLEY LB004 @EricFMorand on deucravacitinib phase 2 for SLE ⭐️Meets primary endpt: SRI(4) ⭐️Secondary endpts: BICLA, LLD, CLASI, jt count, biomarkers improved ⭐️Safety data wo VTE, CVD events Earlier at #EULAR2022, BRAVE trial phase 3 baricitinib: No benefit in SLE @RheumNow https://t.co/3YpPSJcenF
      RT @synovialjoints: Wetterslev et al showed that almost all of 108 axSpA patients in clinical remission flared during ta

      Dr. Antoni Chan synovialjoints

      2 years 5 months ago
      Wetterslev et al showed that almost all of 108 axSpA patients in clinical remission flared during tapering,47% flared at 2/3 to ½ dose and 53% at 1/3 to discontinuation. Higher baseline physician global score was an independent predictor of flare #EULAR2022 @RheumNow POS0298 https://t.co/RELuiB3Enl
      RT @AurelieRheumo: PAISLEY study Phase 2 RCT

      Deucravacitinib in SLE meets primary endpoint wk 32

      Results for dose 3mg

      Aurelie Najm AurelieRheumo

      2 years 5 months ago
      PAISLEY study Phase 2 RCT Deucravacitinib in SLE meets primary endpoint wk 32 Results for dose 3mg BID: *SRI(4) response 58.2% vs. PBO 34% *LLDAS 36% *CLASI 70% *⬇️ SJC No new safety signal Now waiting for Phase 3 👀 @RheumNow LB0004 #EULAR2022 #Lupus https://t.co/2KYSvfq4h7
      RT @RichardPAConway: Dr Coates @DrLauraCoates et al. Domains contributing to MDA achievement in guselkumab treated PsA.

      Richard Conway RichardPAConway

      2 years 5 months ago
      Dr Coates @DrLauraCoates et al. Domains contributing to MDA achievement in guselkumab treated PsA. Physican assessed improved faster than patient assessed. Age, fatigue, BMI, baseline domain score determinants @RheumNow #EULAR2022 POS1067 https://t.co/vPsmeyPjzG

      Podcasts

      • ACR24 - JAK TYK2
      • ACR24 - LUPUS
      • ACR24 - SPONDYLOARTHRITIS

      Catch up on Conference Podcasts

      Featured Video

      Do you get our email newsletter?

      Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

      Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

      Copyright {{ 'now'|date('Y') }} All Rights Reserved.